Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 03, 2022

Comparing the Efficacy of Biosimilar UJVIRA With That of T-DM1 in HER2-Positive Metastatic Breast Cancer

Clinical Breast Cancer


Additional Info

Clinical Breast Cancer
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India
Clin. Breast Cancer 2021 Nov 27;[EPub Ahead of Print], S Chiradoni Thungappa, T Maksud, N Raut, R Nagarkar, U Batra, S Kumar, D Parmar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading